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Background/Aims: To compare the intraocular pressure (IOP)-lowering efﬁ  cacy of travoprost 
0.004%/timolol 0.5% in ﬁ  xed combination with the unﬁ  xed combination of latanoprost 0.005% 
and timolol 0.5% in open-angle glaucoma or ocular hypertension patients with IOP levels below 
18 mmHg on the unﬁ  xed combination of latanoprost 0.005% and timolol 0.5%.
Methods: Following a 30-day open-label run-in with latanoprost QD PM and timolol QD AM, 
subjects with intraocular pressure below 18 mmHg were randomized to continue concomitant 
latanoprost QD PM and timolol QD AM or switch to travoprost 0.004%/timolol 0.5% QD AM 
and vehicle QD PM in masked fashion and were followed for 3 months. The primary efﬁ  cacy 
endpoint was mean IOP reduction from baseline.
Results: There were no clinically relevant or statistically signiﬁ  cant differences in mean 
IOP, mean IOP change from baseline, or percentage IOP change from baseline between the 
two treatment groups. Between-group differences in mean IOP were within ±0.3 mmHg at all 
time points (p  0.384), and between-group differences in mean IOP change from baseline 
were within ±0.4 mmHg at all time points. Overall, 88% of patients whose IOP was less than 
18 mmHg on the unﬁ  xed combination of latanoprost and timolol remained well controlled on 
the same regimen in the masked portion of the study, compared with 92% who remained well 
controlled after switching to travoprost/timolol.
Conclusion: Travoprost 0.004%/timolol 0.5% administered once daily and concomitant 
administration of timolol 0.5% and latanoprost 0.005% produce similar maintenance of IOP-
lowering effect in patients who were previously well controlled on concomitant administration of 
latanoprost and timolol. Patients who are well controlled on latanoprost and timolol concomitant 
therapy can be switched to once-daily therapy with travoprost 0.004%/timolol 0.5% with no 
expected compromise in the safety and efﬁ  cacy of their treatment.
Keywords: travoprost, timolol, glaucoma, intraocular pressure, ﬁ  xed combination
Introduction
Elevated intraocular pressure (IOP) is the only known modiﬁ  able risk factor for the 
development and progression of glaucoma. Reduction of IOP has been shown to prevent 
both the development (Kass et al 2002) and the progression (Collaborative Normal-
Tension Glaucoma Study Group 1998; Heijl et al 2002) of glaucoma. In the European 
Union (EU) and elsewhere, the prostaglandin analogue class of IOP-lowering drugs has 
become the most commonly used ﬁ  rst-line drug class for the treatment of elevated IOP 
in patients with open-angle glaucoma or ocular hypertension (Schwartz and Budenz 
2004). Many patients will require more than one medication to achieve IOP targets Clinical Ophthalmology 2008:2(2) 314
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(Kass et al 2002), and beta-blockers are commonly used as 
adjunctive therapy to prostaglandin analogues in patients 
requiring a multi-drug regimen.
Numerous manufacturers have developed ﬁ  xed combi-
nations of prostaglandin analogues and timolol 0.5%. The 
travoprost 0.004%/timolol 0.5% ﬁ  xed combination (Alcon, 
Ft. Worth) has been shown in clinical trials to be equally 
safe and efﬁ  cacious as concomitant therapy with timolol in 
the morning and travoprost at night (Schuman et al 2005), 
and to have greater efﬁ  cacy than either travoprost or timolol 
monotherapy (Schuman et al 2005; Barnebey et al 2005). The 
purpose of this study was to compare the safety and efﬁ  cacy 
of the ﬁ  xed combination travoprost 0.004%/timolol 0.5% 
versus therapy with the unﬁ  xed combination of latanoprost 
0.005% (Xalatan®, Pﬁ  zer, New York, NY) and timolol 0.5%, 
each dosed once daily (QD), in eyes with IOP less than 
18 mmHg on unﬁ  xed latanoprost and timolol therapy.
Subjects and methods
This was a prospective, multicenter, double-masked, 
active-controlled, parallel-group, randomized clinical trial 
conducted at 20 sites in the United States. The study was 
reviewed and approved by the appropriate institutional 
review board at all participating sites, all participating sub-
jects provided written informed consent to participate, and 
the study was conducted in full compliance with all tenets 
of the Declaration of Helsinki.
Subjects
Eligible subjects were adults 18 years of age or older diag-
nosed with open-angle glaucoma (including pigmentary or 
pseudoexfoliation glaucoma) or ocular hypertension. Sub-
jects must have used both latanoprost 0.005% once daily 
and timolol 0.5% either once or twice daily in both eyes for 
a minimum of 30 days before the screening visit, with an 
IOP measurement below 18 mmHg at the screening visit. 
(All IOP values in this study represent the mean of two con-
secutive measurements if within 4 mmHg; otherwise a third 
measurement was obtained and the value was calculated as 
the mean of the two measurements closest to each other or 
of all three if equally spaced.) Subjects were excluded if they 
met any of the following criteria: females of childbearing 
potential who were pregnant, planned to become pregnant, 
were breastfeeding, or were not using a highly effective 
method of birth control; history of recurrent severe ocular 
inﬂ  ammatory disease, clinically signiﬁ  cant or progressive 
retinal disease, severe ocular pathology precluding the use 
of an ocular prostaglandin, or ocular anomaly preventing 
accurate applanation tonometry; history of ocular trauma 
or intraocular surgery within the past 6 months; or ocular 
infection or inﬂ  ammation or ocular laser surgery within the 
past 3 months. In addition, subjects were excluded if they 
had best-corrected visual acuity worse than 0.6 logMAR in 
either eye; extremely narrow or closed iridocorneal angles; 
cup-to-disc ratio greater than 0.8; central visual ﬁ  eld loss; 
the need for additional IOP-lowering therapy or any form of 
glucocorticoid therapy during the study period; or a history 
of cardiac, pulmonary, hepatic or renal disease precluding 
the use of a topical beta-blocker.
Methods
Medical and ocular history were obtained, and visual acuity, 
slit-lamp examination, Goldmann tonometry, gonioscopy, 
automated perimetry, and dilated fundus examination 
were performed at a Screening visit to establish eligibility. 
Eligible subjects with IOP below 18 mmHg following at 
least 30 days of treatment with latanoprost 0.005% (QD PM) 
and timolol 0.5% (either QD AM or BID) continued to use 
latanoprost QD PM and timolol 0.5% QD AM in both eyes 
for an additional 30 day open-label run-in and then returned 
for an Eligibility visit. At this visit, Goldmann applanation 
was performed at 8 AM, 10 AM, 4 PM, and 8 PM (with 
timolol 0.5% being instilled 15 minutes following the 8 AM 
measurement). Subjects with mean IOP below 18 mmHg in 
both eyes at all time points were randomized in a 1:1 ratio to 
receive either the ﬁ  xed combination of travoprost 0.004%/
timolol 0.5% once daily in both eyes at 8 AM, or to receive 
timolol 0.5% at 8 AM and latanoprost 0.005% at 8 PM in 
both eyes. All subjects were given two masked bottles of 
study medication, one labeled “Morning” and one labeled 
“Evening”. Subjects randomized to the travoprost/timolol 
treatment group were given “Morning” bottles containing the 
ﬁ  xed combination of travoprost 0.004%/timolol 0.5% and 
“Evening” bottles containing vehicle. Subjects randomized 
to the concomitant latanoprost and timolol treatment group 
were given “Morning” bottles containing timolol 0.5% and 
“Evening” bottles containing latanoprost 0.005%. Subjects 
were instructed to instill one drop from the “Morning” bottle 
at 8 AM and one drop from the “Evening” bottle at 8 PM 
every day. Subjects were then seen at Weeks 2 and 6 and 
Month 3 after randomization.
At the Week 2 visit, Goldmann tonometry was performed 
at 8 AM before instilling the “Morning” medication. The 
“Morning” dose was instilled 15 minutes later, and subjects 
were instructed to continue dosing from the “Morning” and 
“Evening” bottles. The Week 6 visit was identical to the Clinical Ophthalmology 2008:2(2) 315
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Week 2 visit. At the Month 3 visit, Goldmann tonometry 
was performed at 8 AM (with “Morning” dosing 15 minutes 
later), 10 AM, 4 PM, and 8 PM. Following the 8 PM IOP 
measurement, a dilated fundus examination was performed, 
after which subjects exited the study. Subjects were queried 
regarding adverse events at all three on-treatment visits.
Statistical analysis
The primary statistical objective of this study was to compare 
the IOP-lowering efﬁ  cacy of the ﬁ  xed combination travoprost 
0.004%/timolol 0.5% to the concomitant administration of 
latanoprost 0.005% and timolol 0.5%. The primary efﬁ  cacy 
parameter was mean IOP change from baseline at Weeks 
2 and 6 and Month 3. One eye per patient was included in 
the analysis, selected as follows: the eye with the higher IOP 
at 8 AM on the eligibility visit, or at 10 AM if equal, or at 
4 PM if equal, or at 8 PM if equal, or the right eye if equal. 
The safety analysis included all subjects who received any 
study medication; the intent-to-treat analysis included all 
subjects who completed at least one on-therapy visit; and 
the per-protocol analysis included all patients in the intent-
to-treat analysis who satisﬁ  ed all protocol criteria.
The primary analysis consisted of a descriptive summary 
of IOP change from baseline for each treatment group. A 
paired t-test was used to further describe the change from 
baseline at each time point. Differences in mean IOP, mean 
IOP change from baseline, and percent IOP change from 
baseline between the two treatment groups were evaluated 
using a two-sample t-test. The experimental hypotheses were 
that there were no differences between treatment groups at 
each of the time points. Sample size was calculated before 
initiation of the study. With 68 evaluable subjects per group, 
mean IOP change from baseline could be estimated to within 
±0.9 mmHg based on the width of a 95% conﬁ  dence inter-
val, with an assumed standard deviation for IOP change of 
3.5 mmHg and using a t-statistic (α = 0.05). Similarly, the 
difference between treatment groups for mean IOP change 
could be estimated to within ±1.2 mmHg using a t-statistic 
(α = 0.05).
Results
Overall, 156 subjects were enrolled in this study and were 
included in the safety analysis; seven subjects were excluded 
from the intent-to-treat analysis, leaving 149 evaluable sub-
jects; and 21 were excluded from the per-protocol analysis, 
leaving 135 evaluable subjects. Efﬁ  cacy data in this report 
are based on the intent-to-treat analysis, as there were no 
signiﬁ  cant differences between the intent-to-treat and the 
per protocol analyses. The mean age of subjects was 66.9 
years; 56% were female; and the ethnic make-up was 60% 
Caucasian, 28% African-American, 9% Hispanic, and 3% 
Asian. These demographics were not statistically different 
between treatment groups.
Mean IOPs at baseline and at each on-therapy time point 
for both treatment groups are given in Table 1. Between-
group differences in mean IOP were within ±0.3 mmHg at all 
baseline and on-therapy time points, and were not statistically 
signiﬁ  cant at any time point.
Mean IOP changes from baseline are given in Table 2. 
Subjects randomized to continue treatment with concomitant 
latanoprost and timolol demonstrated mean IOP changes 
within ±0.3 mmHg compared with baseline. Subjects ran-
domized to switch from latanoprost and timolol concomitant 
therapy to travoprost/timolol ﬁ  xed combination therapy dem-
onstrated mean IOP changes within ±0.5 mmHg compared 
with baseline. The between-group differences in mean IOP 
change were within ±0.4 mmHg at all time points and were 
not statistically signiﬁ  cant at any time point (Figure 1).
Mean percentage IOP change from baseline was also 
similar between groups (Table 2). Subjects randomized to 
the travoprost/timolol ﬁ  xed combination maintained stable 
IOP levels when switched from concomitant latanoprost 
and timolol, with mean percentage IOP changes 4.6% 
across all on-therapy time points. Subjects randomized to 
Table 1 Mean IOP (mmHg) at all time points for both treatment groups
Treatment  Baseline        Week 2  Week 6  Month 3       
  8 AM  10 AM  4 PM  8 PM  8 AM  8 AM  8 AM  10 AM  4 PM  8 PM
Travoprost  0.004%/  15.4  14.6  14.5 14.4 15.3 15.4 15.5 15.1  15.1  14.7
timolol 0.5%
Latanoprost 0.005% +  15.4  14.7  14.6 14.7 15.4 15.6 15.5 14.8  14.9  14.8
timolol 0.5%
Difference  –0.0 –0.1  –0.1 –0.3  –0.1  –0.3  0.1  0.3 0.2 –0.1
P-value*  0.9773  0.8606  0.8637 0.3839 0.8573 0.5422 0.8783 0.4497  0.6831  0.7982
*P-value from two sample t-test.
Mean IOP values and associated differences have been rounded to one decimal place for presentation.Clinical Ophthalmology 2008:2(2) 316
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continue on concomitant latanoprost and timolol therapy 
also maintained stable IOP levels, with mean percentage 
IOP changes 2.6% across all on-therapy time points. The 
between-group differences in mean percentage IOP change 
were within ±3.7% at all time points and were not statistically 
signiﬁ  cant at any time point.
All subjects had mean IOP below 18 mmHg following 
the 30-day run-in with concomitant latanoprost and timolol 
therapy, with up to 92% of subjects in the travoprost 0.004%/
timolol 0.5% treatment group and up to 88% of subjects in 
the unﬁ  xed latanoprost and timolol treatment group main-
taining mean IOP less than 18 mmHg after randomization 
(Figure 2). The percentages of patients who maintained IOP 
below 18 mmHg at all on-therapy visits were 59% and 56%, 
respectively, for the ﬁ  xed travoprost 0.004%/timolol 0.5% and 
unﬁ  xed latanoprost and timolol treatment groups (p = 0.72).
Both treatments were well tolerated by subjects; adverse 
events (AEs) were predominately nonserious, generally mild 
or moderate in intensity, and no subject discontinued the study 
due to an AE. AEs were reported by 30.4% (24/79) of the 
subjects in the travoprost/timolol group and by 40.3% (31/77) 
of the subjects in the latanoprost and timolol concomitant 
group. The most frequently reported treatment-related AEs 
in the travoprost 0.004%/timolol 0.5% group were ocular 
hyperemia, ocular discomfort, ocular pruritus, and blurred 
vision (incidence 2.5% each), while the most frequently 
reported treatment-related AE in the latanoprost and timolol 
group was ocular hyperemia (incidence 2.6%). There were 
no clinically relevant differences between the treatment 
groups in the overall safety population. Five serious adverse 
events were reported but all were assessed as unrelated to 
the study drug.
Table 2 Mean IOP change from baseline (mmHg) and mean percent IOP change from baseline
Treatment  Week 2  Week 6  Month 3     
  8 AM  8 AM  8 AM  10 AM  4 PM  8 PM
Travoprost 0.004%/timolol 0.5%
Mean IOP change  −0.1  −0.0 0.1  0.5  0.5  0.4
Mean % IOP change  0.0  0.3  1.2  4.6  4.5  3.4
N 73  73  73  71  71  71
Latanoprost 0.005% + timolol 0.5%
Mean IOP change  −0.0 0.2  0.0  0.1  0.3  0.2
Mean % IOP change  −0.2 1.3  0.3  0.9  2.6  2.0
N 75  75  75  73  73  73
Estimates based on descriptive statistics.
Mean IOP values and associated differences have been rounded to one decimal place for presentation.
Figure 1 Difference in mean IOP change from baseline between travoprost/timolol and latanoprost + timolol groups.
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Discussion
The travoprost 0.004%/timolol 0.5% ﬁ  xed combination 
dosed once daily in the morning provided similar IOP 
control to concomitant therapy with timolol 0.5% dosed 
once daily in the morning and latanoprost 0.005% dosed 
once daily in the evening. Subjects who were well controlled 
(mean IOP 18 mmHg) on concomitant latanoprost and 
timolol maintained comparable IOP control when switched 
to once-daily treatment with the travoprost/timolol ﬁ  xed 
combination. These ﬁ  ndings are consistent with prior reports 
demonstrating similar IOP-lowering efﬁ  cacy (Netland et al 
2001; Parrish et al 2003) and circadian IOP control (Orzalesi 
et al 2006) between travoprost and latanoprost.
In the present study, the travoprost/timolol fixed 
combination was dosed in the morning. Several studies have 
demonstrated that morning versus evening dosing of travoprost 
provides equivalent mean 24-hour IOP reduction (Denis et al 
2006; Konstas et al 2006).
The results of this study support the conclusion that patients 
with open-angle glaucoma or ocular hypertension controlled 
on unﬁ  xed latanoprost and timolol therapy are likely to be 
equally well controlled on once-daily travoprost/timolol in 
ﬁ  xed combination. Up to 92% of subjects in the travoprost/
timolol group and up to 88% of subjects in the unﬁ  xed latano-
prost and timolol group maintained IOP below 18 mmHg after 
randomization, with 59% and 56%, respectively, demonstrat-
ing IOP below 18 mmHg at all on-therapy visits.
Switching from unﬁ  xed latanoprost and timolol therapy 
to travoprost/timolol ﬁ  xed combination therapy represents 
two important regimen changes: a reduction in the number 
of medication bottles in the regimen, and a reduction in the 
number of drops per day. A regimen with fewer medications 
equates to fewer co-payments or lower overall drug costs for 
patients without prescription drug insurance. Fewer drops 
per day reduces the complexity of the therapeutic regimen, 
which is likely to improve adherence (Patel and Spaeth 1995). 
Fixed combination therapy also reduces the washout effect 
whereby rapid sequential instillation of multiple eye drop 
medications reduces absorption of the earlier drops due to 
washout by the later drops (Chrai et al 1974). Furthermore, 
administration of two medications in a single drop minimizes 
exposure of the ocular surface to other drop components, 
Figure 2 Percentage of patients who maintained IOP less than 18 mmHg at each study visit.
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including the preservative benzalkonium chloride, which has 
been linked to ocular surface changes (de Jong et al 1994), 
dry eye symptoms ( Pisella et al 2002; Mundorf et al 2003) and 
chronic subclinical conjunctival inﬂ  ammation (Broadway 
et al 1994a; Noecker et al 2004) that may reduce the success 
of eventual glaucoma ﬁ  ltration surgery (Lavin et al 1990; 
Broadway et al 1993, 1994b; Baudouin 1996).
The safety of the travoprost/timolol ﬁ  xed combination 
has been established in large, multicenter, Phase III clinical 
trials (Barnebey et al 2005; Hughes et al 2005; Schuman 
et al 2005). In the present study, the travoprost/timolol ﬁ  xed 
combination was found to have comparable safety to the 
concomitant use of latanoprost and timolol. This is expected 
given that the nature of side effects between the various 
prostaglandin agents has been comparable, with only minor 
differences in the relative frequency of these side effects 
(Netland et al 2001; Parrish et al 2003).
In conclusion, subjects with open-angle glaucoma or 
ocular hypertension with IOP 18 mmHg on concomitant 
therapy with latanoprost 0.005% in the evening and timolol 
0.5% in the morning can be safety switched to once-daily 
dosing with the ﬁ  xed combination travoprost 0.004%/timolol 
0.5% with no statistically signiﬁ  cant or clinically relevant 
change in IOP control and no additional safety risks.
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